Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

OncoTherapy Science stock price, quote, forecast and news

4564.T
JP3202150003
726692

Price

40.00
Today +/-
+0
Today %
+0 %
P

OncoTherapy Science stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the OncoTherapy Science stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the OncoTherapy Science stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the OncoTherapy Science stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze OncoTherapy Science's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

OncoTherapy Science Stock Price History

DateOncoTherapy Science Price
9/10/202440.00 undefined
9/9/202440.00 undefined
9/6/202441.00 undefined
9/5/202444.00 undefined
9/4/202444.00 undefined
9/3/202445.00 undefined
9/2/202440.00 undefined
8/30/202445.00 undefined
8/29/202447.00 undefined
8/28/202449.00 undefined
8/27/202451.00 undefined
8/26/202454.00 undefined
8/23/202451.00 undefined
8/22/202453.00 undefined
8/21/202457.00 undefined
8/20/202451.00 undefined
8/19/202451.00 undefined
8/16/202449.00 undefined
8/15/202451.00 undefined
8/14/202450.00 undefined
8/13/202451.00 undefined

OncoTherapy Science Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into OncoTherapy Science, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by OncoTherapy Science from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects OncoTherapy Science’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of OncoTherapy Science. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into OncoTherapy Science’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing OncoTherapy Science’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on OncoTherapy Science’s growth potential.

OncoTherapy Science Revenue, EBIT and net profit per share

DateOncoTherapy Science RevenueOncoTherapy Science EBITOncoTherapy Science Net Income
2024610.12 M undefined-1.12 B undefined-1.29 B undefined
20231.13 B undefined-1.11 B undefined-1.12 B undefined
20221.15 B undefined-2.05 B undefined-2.57 B undefined
2021332.48 M undefined-1.64 B undefined-1.56 B undefined
2020316.22 M undefined-2.19 B undefined-2.24 B undefined
2019280.59 M undefined-2.95 B undefined-2.93 B undefined
2018211.25 M undefined-2.99 B undefined-2.85 B undefined
2017286.67 M undefined-3 B undefined-3 B undefined
2016266.9 M undefined-2.98 B undefined-2.79 B undefined
2015769.96 M undefined-1.96 B undefined-1.33 B undefined
20141.02 B undefined-3.79 B undefined-3.68 B undefined
20133.28 B undefined-1.11 B undefined-1.1 B undefined
20126.22 B undefined1.18 B undefined727 M undefined
20115.36 B undefined223.3 M undefined566.8 M undefined
20105.26 B undefined332 M undefined510.2 M undefined
20093.33 B undefined40.6 M undefined148.2 M undefined
20081.97 B undefined-378.8 M undefined-202.1 M undefined
2007804.5 M undefined-1.35 B undefined-1.32 B undefined
20061.16 B undefined-833.4 M undefined-525.7 M undefined
20051.58 B undefined35.1 M undefined17.4 M undefined

OncoTherapy Science Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
00.981.581.581.160.81.973.335.265.366.223.281.020.770.270.290.210.280.320.331.151.130.61
--61.850.13-26.33-30.93145.2768.7158.011.9816.08-47.34-68.97-24.39-65.417.52-26.2232.7012.865.06247.29-1.65-46.21
-48.7246.5828.10-51.89-132.84-3.859.5612.9411.3424.23--------15.825.729.803.62-29.02
-0.060.480.740.44-0.6-1.07-0.080.320.680.611.510000000-0.050.020.110.04-0.18
-0.10.250.460.04-0.83-1.35-0.380.040.330.221.18-1.11-3.79-1.96-2.98-3-2.99-2.95-2.19-1.64-2.05-1.11-1.12
-25.6429.092.22-71.56-167.66-19.171.206.324.1619.03-33.96-372.17-255.14-1,120.30-1,050.35-1,416.11-1,054.64-692.72-493.07-177.97-97.53-183.61
-10419429717-525-1,323-202148510566727-1,103-3,676-1,334-2,788-3,002-2,851-2,934-2,238-1,561-2,571-1,118-1,288
--286.5453.09-94.28-3,188.24152.00-84.73-173.27244.5910.9828.45-251.72233.27-63.71109.007.68-5.032.91-23.72-30.2564.70-56.5115.21
9090107.9119.196.797.898.8116.4117.7118.2117.3107.9130.4146.79147147.03147.03147.5163.05176.26187.47192.64212.78
-----------------------
Details

Keystats

ⓘ

Revenue and Growth

The OncoTherapy Science Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the OncoTherapy Science is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                             
0.140.249.829.838.927.728.337.878.799.068.948.517.8316.0713.0710.076.744.864.712.91.841.120.53
00.130.450.30.240.170.020.250.30.882.81.360.030.030000.020.030.150.40.120.04
0001892170000002520000000000153.48
017424826474935252426262215.7813.0114.5625.3324.9341.07231.0499.6274
1965225615590295523524330932256131202.39201.14278.83155.16109.88101.69132.8681.927.01
0.140.410.3410.379.448.088.498.469.6510.4912.0911.0618.1416.2613.2910.297.035.064.883.192.61.420.82
426117406411367365364347447358306279254.39276.96219.8581.97200.78113.4894.940.0200
00050501012829323543000000000000
00200000000000000000000
015741141721691601351371531611099352.2124.5215.93284.949.386.124.72000
00000000000000000000000
316145958586559587066666665.2473.1768.14120.55101.6290.4774.3484.6389.1849.51
757207629691695618587574705628481438371.84374.66303.87987.46311.77210.0717484.6589.1849.51
0.140.4510.541110.138.779.119.0510.2211.212.7211.5418.5816.6313.6610.598.025.375.093.372.691.510.87
                                             
0.10.13.433.443.463.473.483.493.513.553.563.579.089.129.139.140.050.331.420.050.790.790.05
0.090.096.396.46.426.436.456.466.476.516.536.5412.0512.0912.112.121.3121.5922.6824.0524.7924.7926.32
-0.110.090.390.41-0.12-1.37-1.55-1.35-0.690.141.090.16-3.48-5.14-8.11-11.12-14.03-17.04-19.38-21.03-23.6-24.73-26.02
00000000095-1-7-9.72-8.74-8.24-9.25-10.060000-0
00000000000000000000000
0.090.2810.2110.259.768.528.388.69.2910.2111.1810.2717.6416.0613.1110.17.324.874.733.081.980.860.35
00000000000000000000000
13192112000000000000000000
0.010.140.310.70.340.250.480.390.830.821.2210.590.340.370.370.310.370.240.190.60.610.36
00000000000000000000000
00000000000000000000000
0.010.170.320.720.350.250.480.390.830.821.2210.590.340.370.370.310.370.240.190.60.610.36
5000000111000000000000000106.85
0010281324213928231913.9511.2511.212.944.613.2720.3400
0000002713078179161191192.76165.98107.36122.61124.52113.4494.3699.7147.0547.17
5001028132142151117207184210206.71177.23118.57135.55129.13116.7196.36100.0447.05154.02
0.060.170.330.750.370.250.620.410.830.941.431.190.80.540.550.490.440.50.360.290.70.660.51
0.140.4510.5410.9910.138.7799.0110.1211.1412.6111.4618.4416.6113.6610.597.765.375.093.372.691.510.87
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of OncoTherapy Science provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand OncoTherapy Science's financial health and stability.

Assets

OncoTherapy Science's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that OncoTherapy Science must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of OncoTherapy Science after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into OncoTherapy Science's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-0.10.250.530.04-0.54-1.33-0.230.080.570.621.28-1.13-3.72-1.36-2.79-3-2.92-3.19-2.24-1.56-2.57-1.12
15295611111811412011915714313599106125891483913949160
0000000000000000000000
0-0.05-0.430.16-0.110.050.42-0.520.17-0.63-1.750.341.88-0.04-0.06-0.07-0.210.19-0.11-0.17-0.060.29
342921-365358816529523520086-407-173-11-5723528-7953730
1,0001,00000000000000000000000
0097244-564454693717-345-54174452222
-0.10.210.160.28-0.55-1.090.35-0.221.020.44-0.09-0.46-1.65-1.7-2.9-2.99-3.04-2.37-2.28-1.76-2.07-0.79
-5-40-176-186-401-88-104-147-121-241-60-54-41-56-116-11-408-71-131-43-456-5
-0.01-0.05-0.18-5.294.6-3.61-2.445.9-3.13-0.753.44-0.01-13.041.8810.88-0.01-0.45-0.07-0.03-0.05-0.47-0.02
-0-0.010-5.15-3.52-2.346.05-3-0.53.50.04-131.94110-0.04-00.1-0.01-0.01-0.01
0000000000000000000000
49-500000111-11100000000000000
0.1909.60.020.040.010.040.020.020.070.030.0211.020.070.01000.552.1601.470
0.24-0.059.60.020.040.010.15-0.090.020.070.030.0211.020.070.0100.150.572.1601.480.1
000000000000000015012001295
0000000000000000000000
0.130.19.58-4.994.09-4.69-1.955.59-2.08-0.233.38-0.44-3.670.258-3-3.33-1.88-0.14-1.81-1.06-0.72
-100.8167.2-20.192.8-952.6-1,180241.8-371902.8199.1-151.6-510.3-1,691-1,758.89-3,014.93-3,000-3,444.84-2,444.78-2,406.91-1,806.54-2,530.17-800.3
0000000000000000000000

OncoTherapy Science stock margins

The OncoTherapy Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OncoTherapy Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OncoTherapy Science.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the OncoTherapy Science's sales revenue. A higher gross margin percentage indicates that the OncoTherapy Science retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the OncoTherapy Science's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the OncoTherapy Science's total revenue generated. When comparing the revenue margin year over year, investors can gauge the OncoTherapy Science's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the OncoTherapy Science. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the OncoTherapy Science's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

OncoTherapy Science Margin History

OncoTherapy Science Gross marginOncoTherapy Science Profit marginOncoTherapy Science EBIT marginOncoTherapy Science Profit margin
2024-29.13 %-183.7 %-211.13 %
20233.67 %-97.49 %-98.57 %
20229.87 %-177.92 %-222.9 %
20215.88 %-492.65 %-469.7 %
2020-15.85 %-692.46 %-707.92 %
2019-29.13 %-1,052.72 %-1,046.01 %
2018-29.13 %-1,414.71 %-1,349.62 %
2017-29.13 %-1,047.98 %-1,047.23 %
2016-29.13 %-1,116.85 %-1,044.88 %
2015-29.13 %-254.88 %-173.37 %
2014-29.13 %-371.97 %-361.23 %
2013-29.13 %-33.98 %-33.66 %
201224.24 %19.03 %11.68 %
201111.35 %4.16 %10.57 %
201012.94 %6.31 %9.7 %
20099.56 %1.22 %4.45 %
2008-3.87 %-19.2 %-10.24 %
2007-132.77 %-167.64 %-164.5 %
2006-51.89 %-71.55 %-45.13 %
200528.15 %2.22 %1.1 %

OncoTherapy Science Stock Sales Revenue, EBIT, Earnings per Share

The OncoTherapy Science earnings per share therefore indicates how much revenue OncoTherapy Science has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue OncoTherapy Science earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates OncoTherapy Science's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of OncoTherapy Science’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating OncoTherapy Science's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

OncoTherapy Science Revenue, EBIT and net profit per share

DateOncoTherapy Science Sales per ShareOncoTherapy Science EBIT per shareOncoTherapy Science Earnings per Share
20242.87 undefined-5.27 undefined-6.05 undefined
20235.89 undefined-5.74 undefined-5.81 undefined
20226.15 undefined-10.95 undefined-13.72 undefined
20211.89 undefined-9.29 undefined-8.86 undefined
20201.94 undefined-13.43 undefined-13.73 undefined
20191.9 undefined-20.03 undefined-19.9 undefined
20181.44 undefined-20.33 undefined-19.39 undefined
20171.95 undefined-20.43 undefined-20.42 undefined
20161.82 undefined-20.28 undefined-18.97 undefined
20155.25 undefined-13.37 undefined-9.09 undefined
20147.81 undefined-29.03 undefined-28.19 undefined
201330.37 undefined-10.32 undefined-10.22 undefined
201253.06 undefined10.09 undefined6.2 undefined
201145.36 undefined1.89 undefined4.8 undefined
201044.67 undefined2.82 undefined4.33 undefined
200928.59 undefined0.35 undefined1.27 undefined
200819.97 undefined-3.83 undefined-2.05 undefined
20078.23 undefined-13.79 undefined-13.53 undefined
200612.05 undefined-8.62 undefined-5.44 undefined
200513.27 undefined0.29 undefined0.15 undefined

OncoTherapy Science business model

OncoTherapy Science Inc is a rising company that focuses on the research and development of novel cancer therapies. The company takes pride in being able to combine the latest scientific findings with cutting-edge technologies to develop highly effective drugs and therapies that can improve the lives of cancer patients. The company is based in Japan and was founded in 2001. Since its inception, it has become one of the leading companies in cancer research and its products are available worldwide. OncoTherapy Science Inc's business model is based on the development and commercialization of new innovative cancer therapies. The company utilizes the latest technologies and research findings to achieve groundbreaking advancements in cancer treatment. These innovative therapies have the potential to improve the survival and quality of life of cancer patients. OncoTherapy Science Inc divides its activities into various areas. This includes the research and development of drugs, the clinical testing of new therapies, and the production and commercialization of cancer therapies. The research and development of new drugs form the core of OncoTherapy Science Inc's activities. The company continuously invests in researching new treatment approaches to improve the effectiveness and safety of cancer therapies. Advanced technologies such as genome sequencing and molecular diagnostics are utilized to develop personalized therapies tailored to specific types of cancer and patients. OncoTherapy Science Inc also conducts extensive clinical trials to evaluate the effectiveness and safety of its therapies. The success rate of clinical studies is very high, and many of the therapies have already received approval from regulatory authorities. Another important area of OncoTherapy Science Inc is the production and commercialization of cancer therapies. The company works closely with its distribution partners to ensure that its products are available in many countries and regions. OncoTherapy Science Inc's therapies are recommended by many oncologists and used in leading clinical institutions worldwide. Products of OncoTherapy Science Inc include a range of innovative cancer therapies. These include antibody-based drugs, immunotherapies, RNA-based therapies, and chemotherapy. These therapies have the potential to improve the effectiveness of cancer treatment and enhance the quality of life of cancer patients. An example of an innovative therapy by OncoTherapy Science Inc is OTS964, a new chemotherapeutic agent for the treatment of pancreatic cancer and other cancers. OTS964 inhibits the enzyme TOPK, which is overexpressed in many types of cancer, leading to the death of cancer cells. This therapy has shown promising results in animal models and is currently being tested in clinical trials. OncoTherapy Science Inc aims to contribute to improving the quality of life of cancer patients. The company relies on a combination of innovative research, state-of-the-art technology, and close collaboration with other industry stakeholders to achieve a leading position in cancer research. With its strong market position and commitment to cancer research, OncoTherapy Science Inc is a company that will achieve much in the future. OncoTherapy Science is one of the most popular companies on Eulerpool.com.

OncoTherapy Science SWOT Analysis

Strengths

OncoTherapy Science Inc has a strong reputation for its innovative research and development efforts, continuously pushing boundaries in the field of oncology.

The company's commitment to staying at the forefront of scientific advancements enables it to develop groundbreaking therapies that could revolutionize cancer treatment.

OncoTherapy Science Inc possesses a robust intellectual property portfolio, safeguarding its innovative discoveries and ensuring exclusivity in the market.

This intellectual property gives the company a competitive advantage, attracting potential partners and investors who seek to benefit from its proprietary technologies.

Weaknesses

Despite its strengths, OncoTherapy Science Inc currently faces challenges in establishing a significant market presence.

The company may struggle to effectively commercialize its therapies due to limited brand recognition and a comparatively smaller market share compared to established competitors.

OncoTherapy Science Inc heavily relies on research funding to sustain its operations and drive innovation.

Any disruption or reduction in funding sources can affect the company's ability to advance its research programs and develop new therapies, potentially hindering its growth.

Opportunities

The increasing prevalence of cancer worldwide presents a significant opportunity for OncoTherapy Science Inc.

As the demand for more effective and personalized cancer treatments continues to rise, the company's innovative therapies have the potential to address unmet medical needs and capture a larger market share.

OncoTherapy Science Inc can explore strategic collaborations and partnerships with other pharmaceutical companies, academic institutions, and research centers.

Such collaborations can provide access to additional resources, expertise, and financial support, facilitating accelerated development and commercialization of its therapies.

Threats

The oncology market is highly competitive, with numerous established pharmaceutical companies actively researching and developing cancer treatments.

OncoTherapy Science Inc must navigate this competitive landscape, facing challenges in gaining market share and differentiating its offerings from those of larger, well-known competitors.

The regulatory complexities and stringent compliance requirements surrounding drug development and commercialization pose potential threats to OncoTherapy Science Inc.

Non-compliance or delays in obtaining necessary approvals can impede the company's ability to bring its therapies to market in a timely manner, impacting its revenue generation and overall success.

OncoTherapy Science Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

OncoTherapy Science historical P/E ratio, EBIT, and P/S ratio.

OncoTherapy Science shares outstanding

The number of shares was OncoTherapy Science in 2023 — This indicates how many shares 192.644 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue OncoTherapy Science earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates OncoTherapy Science's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of OncoTherapy Science’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating OncoTherapy Science's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

OncoTherapy Science Stock splits

In OncoTherapy Science's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for OncoTherapy Science.

OncoTherapy Science list of shareholders

%
Name
Stocks
Change
Date
4.60566 % Nakamura (Yusuke)12,511,00009/30/2023
2.68734 % SMBC Trust Bank (Trust)7,300,00009/30/2023
2.68734 % Shionogi & Co Ltd7,300,00003/31/2023
2.15355 % Nakatsuru (Shuichi)5,850,00009/30/2023
1.45153 % Furukawa (Yoichi)3,943,00009/30/2023
0.92032 % Arakawa (Hirofumi)2,500,00009/30/2023
0.62040 % JPMorgan Securities Japan Co., Ltd.1,685,2831,685,2839/30/2023
0.36003 % Kitamura (Kazuko)978,000978,0009/30/2023
0.00029 % Daiwa Securities Co., Ltd.800-26,5005/15/2023
0 % Simplex Asset Management Co., Ltd.0-302,20010/31/2023
1
2

OncoTherapy Science Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Cosmo Bio Stock
Cosmo Bio
SupplierCustomer0,81-0,020,180,550,760,68
Shionogi Stock
Shionogi
SupplierCustomer0,360,390,230,56-0,67-0,72
CrystalGenomics Stock
CrystalGenomics
SupplierCustomer0,350,490,200,670,790,80
Kyowa Kirin Stock
Kyowa Kirin
SupplierCustomer0,290,030,240,680,79-0,25
Theragen Etex Stock
Theragen Etex
SupplierCustomer-0,040,540,260,680,890,84
1

Most common questions regarding OncoTherapy Science

What values and corporate philosophy does OncoTherapy Science represent?

OncoTherapy Science Inc represents values of innovation, integrity, and commitment to advancing cancer treatments. The company's corporate philosophy revolves around conducting groundbreaking research to develop effective therapies for oncology patients. With a focus on precision medicine, OncoTherapy Science Inc aims to deliver personalized and targeted treatments for individuals battling cancer. Their dedication to scientific excellence, collaboration with key stakeholders, and patient-centric approach sets them apart in the field of oncology. OncoTherapy Science Inc's commitment to improving patient outcomes and revolutionizing cancer care aligns with their vision of becoming a global leader in precision oncology.

In which countries and regions is OncoTherapy Science primarily present?

OncoTherapy Science Inc is primarily present in Japan.

What significant milestones has the company OncoTherapy Science achieved?

OncoTherapy Science Inc, a leading biotechnology company, has achieved several significant milestones in its journey. The company's dedication to cutting-edge research and innovation has resulted in remarkable achievements. OncoTherapy Science Inc has successfully developed and commercialized groundbreaking therapies for various types of cancers, revolutionizing the treatment landscape. Moreover, the company has received multiple accolades for its exceptional contributions to the field of oncology. OncoTherapy Science Inc's relentless pursuit of excellence has positioned it as a key player in the fight against cancer, making it a trusted name in the industry. With numerous achievements under its belt, OncoTherapy Science Inc continues to pave the way for advancements in cancer treatment.

What is the history and background of the company OncoTherapy Science?

OncoTherapy Science Inc is a leading biotechnology company specializing in innovative cancer therapies. With a rich history spanning several successful years, OncoTherapy Science Inc has consistently demonstrated its commitment to revolutionizing cancer treatment through cutting-edge research and development. The company has a strong background in targeted therapies, utilizing advanced techniques to understand and combat the complex mechanisms of cancer. OncoTherapy Science Inc prioritizes patient-centric approaches, seeking to improve clinical outcomes and ultimately save lives. Their dedicated team of scientists and researchers are relentlessly working towards discovering breakthrough treatments for various types of cancer, cementing their position as a trusted leader in the field of oncology.

Who are the main competitors of OncoTherapy Science in the market?

The main competitors of OncoTherapy Science Inc in the market include pharmaceutical companies such as Pfizer, Merck & Co., and Novartis.

In which industries is OncoTherapy Science primarily active?

OncoTherapy Science Inc is primarily active in the biotechnology industry.

What is the business model of OncoTherapy Science?

The business model of OncoTherapy Science Inc revolves around developing cutting-edge therapies for cancer treatment. The company focuses on leveraging its innovative technologies and expertise in molecular biology to discover and develop novel drugs targeting cancer cells. OncoTherapy Science Inc aims to improve patient outcomes by advancing precision medicine through personalized therapies. By analyzing the genetic makeup of tumor cells, the company identifies specific targets and develops therapeutics to inhibit their growth. With a strong emphasis on research and development, OncoTherapy Science Inc strives to bring breakthrough treatments to market, offering hope to cancer patients worldwide.

What is the P/E ratio of OncoTherapy Science 2024?

The OncoTherapy Science P/E ratio is -6.61.

What is the P/S ratio of OncoTherapy Science 2024?

The OncoTherapy Science P/S ratio is 13.95.

What is the AlleAktien quality score of OncoTherapy Science?

The AlleAktien quality score for OncoTherapy Science is 3/10.

What is the revenue of OncoTherapy Science 2024?

The OncoTherapy Science revenue is 610.12 M JPY.

How high is the profit of OncoTherapy Science 2024?

The OncoTherapy Science profit is -1.29 B JPY.

What is the business model of OncoTherapy Science

OncoTherapy Science Inc. is a leading biopharmaceutical company focused on the development of innovative cancer therapies. It offers a comprehensive portfolio of therapeutics and diagnostics to improve the treatment and cure of cancer patients worldwide. The company is divided into different divisions to enable effective development of cancer therapies, including research and development, production, marketing, and distribution of cancer drugs. The research and development department of OncoTherapy Science Inc. consists of a team of scientists and researchers who focus on identifying new therapeutic targets and developing innovative therapeutics. The research department has already made significant advances in the field of personalized medicine. OncoTherapy Science Inc. provides a wide range of products to offer better therapy options for cancer patients, including innovative antibody-based therapeutics, including immunotherapies, cytokines, antibody conjugates, mono- and polyclonal antibodies. The company also works on the development of diagnostics to enhance the effectiveness of therapy options, offering tests and diagnostic instruments that improve the accuracy of diagnosis and help patients choose the best possible therapy option. OncoTherapy Science Inc. also has a production department that utilizes modern technologies and automated production lines. The production facilities are set up according to the latest GMP standards to ensure that the products are of the highest quality and purity and comply with FDA regulations. The company markets and distributes its products worldwide through a network of partners and distributors. It has branches in different countries and collaborations with leading research institutions and universities around the world to support its research and development. In summary, OncoTherapy Science Inc. is a company focused on the research, development, and marketing of cancer therapeutics and diagnostics. It aims to provide better treatment options for cancer patients worldwide and has already made significant progress. With its wide range of innovative products, modern production facility, and strong research and development program, OncoTherapy Science Inc. is a leading company in cancer research and therapy.

What is the OncoTherapy Science dividend?

OncoTherapy Science pays a dividend of 0 JPY distributed over payouts per year.

How often does OncoTherapy Science pay dividends?

The dividend cannot currently be calculated for OncoTherapy Science or the company does not pay out a dividend.

What is the OncoTherapy Science ISIN?

The ISIN of OncoTherapy Science is JP3202150003.

What is the OncoTherapy Science WKN?

The WKN of OncoTherapy Science is 726692.

What is the OncoTherapy Science ticker?

The ticker of OncoTherapy Science is 4564.T.

How much dividend does OncoTherapy Science pay?

Over the past 12 months, OncoTherapy Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoTherapy Science is expected to pay a dividend of 0 JPY.

What is the dividend yield of OncoTherapy Science?

The current dividend yield of OncoTherapy Science is .

When does OncoTherapy Science pay dividends?

OncoTherapy Science pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of OncoTherapy Science?

OncoTherapy Science paid dividends every year for the past 0 years.

What is the dividend of OncoTherapy Science?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is OncoTherapy Science located?

OncoTherapy Science is assigned to the 'Health' sector.

Wann musste ich die Aktien von OncoTherapy Science kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of OncoTherapy Science from 9/12/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did OncoTherapy Science pay the last dividend?

The last dividend was paid out on 9/12/2024.

What was the dividend of OncoTherapy Science in the year 2023?

In the year 2023, OncoTherapy Science distributed 0 JPY as dividends.

In which currency does OncoTherapy Science pay out the dividend?

The dividends of OncoTherapy Science are distributed in JPY.

All fundamentals about OncoTherapy Science

Our stock analysis for OncoTherapy Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoTherapy Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.